M. Imran Aslam a , b , c , d , Jinu Abraham c , Atiya Mansoor e , Brian J. Druker a , b , f , 1 , Jeffrey W. Tyner a , g , 1 , 2 , and Charles Keller c , 1 , 2 a Knight Cancer Institute, Oregon Health and Science University, Portland, OR ... PNAS, 3 days ago
3 images for "brian druker"
Dr. Brian Druker heads the OHSU Knight Cancer Institute. Northwest News Network, Chris Lehman Northwest News Network, Chris Lehman Dr. Brian Druker heads the OHSU Knight Cancer Institute. Northwest News Network, Chris Lehman Researcher ...Oregon Public Broadcasting, 1 month ago
- MolecularMD, Inc., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, today announced certification of its Next Generation Sequencing (NGS) ...4 Traders, 2 weeks ago MolecularMD Receives CLIA Certification for Its Second Next Generation Sequencing Laboratory Pharmacy Choice, 2 weeks ago
More from: BioMedReports, Reuters...and 3 other sources
MolecularMD Launches NanoString Platform for Multiplexed Digital Evaluation of Gene Expression and Copy Number Variation in Clinical Specimens
- MolecularMD Corp. today announced that it has launched the NanoString nCounter® Analysis System for multiplex biomarker evaluation in support of oncology clinical drug development. Several types of gene panels are offered for clinical trial ...4 Traders, 1 month ago
As cancer cases and deaths shoot up, doctors and patients are outraged by the exorbitant cost of medicines and call for action to be taken. MY Global Trends article last week on the effects of the Trans-Pacific Partnership on access to cancer ...TheStar.com.my, 1 month ago
(Targeted News Service Via Acquire Media NewsEdge) Targeted News Service Targeted News Service ALEXANDRIA, Va., Feb. 27 -- The following federal patents were awarded to inventors in New York. *** Xerox Assigned Patent for Methods and Systems for ...TMC Net, 1 month ago
MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
- MolecularMD Corp. today announced that it has entered into a collaboration with Novartis Pharmaceuticals Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have ...4 Traders, 1 month ago
on your WebpageAdd Widget >Get your members hooked!